NewLimit Raises $435 Million to Launch Longevity Liver Medicine Clinical Trial

The longevity startup NewLimit is preparing to launch its first clinical trial for a liver medicine. This move follows a massive infusion of capital, with the company raising $435 million in new funding.

Strategic Funding and Market Valuation

The Series C fundraising round was led by Founders Fund, a prominent Silicon Valley venture capital firm co-founded by Peter Thiel. Other contributors included Thrive Capital, Lilly Ventures, and tech entrepreneurs Daniel Gross and Nat Friedman.

According to co-founder and CEO Jacob Kimmel, this latest investment brings the company’s valuation to approximately $3.1 billion.

Did You Know? NewLimit was established in 2021 by a multidisciplinary team including Coinbase CEO and co-founder Brian Armstrong, stem cell biologist Jacob Kimmel, and bioengineer Blake Byers.

Rapid Growth in South San Francisco

Based in South San Francisco, NewLimit has maintained a fast pace of growth and investor attraction. This recent round is the third time the company has announced fundraising within a single year.

Prior to the Series C, the startup secured a $130 million Series B round in May 2025, followed by an additional $45 million in October.

Expert Insight: Samantha Carter notes that the convergence of high-profile tech leadership and specialized stem cell biology suggests a strategic attempt to apply Silicon Valley’s rapid scaling models to complex biological challenges. The sheer volume of capital raised in a short window indicates a high-stakes bet on the feasibility of longevity-focused medicine.

Future Implications and Next Steps

The primary objective for the newly acquired funds is the initiation of clinical trials. This phase could determine the efficacy and safety of the company’s liver medicine.

Depending on the results of these trials, NewLimit may seek further expansions of its medical pipeline. The company is likely to continue leveraging its connections within the venture capital and tech sectors to sustain its operations.

Frequently Asked Questions

What is the current valuation of NewLimit?

CEO Jacob Kimmel stated that the company is now valued at around $3.1 billion.

Who led the most recent funding round?

The Series C financing was led by Founders Fund, the venture capital firm co-founded by Peter Thiel.

What is the purpose of the new $435 million investment?

NewLimit plans to use the funding to launch its first clinical trial of a liver medicine.

How do you feel about the increasing involvement of tech entrepreneurs in the field of longevity medicine?